Heart transplant patients may get new shield against artery disease

NCT ID NCT04770012

First seen May 09, 2026 · Last updated May 14, 2026 · Updated 1 time

Summary

This study tests if starting antiplatelet medication (blood thinners) soon after a heart transplant can prevent a common complication called cardiac allograft vasculopathy (CAV), which narrows the heart's arteries. About 135 adult heart transplant recipients will receive either aspirin, clopidogrel, or a placebo to see if early treatment is feasible and effective. The goal is to keep the new heart healthier longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • St.Pauls Hospital

    RECRUITING

    Vancouver, British Columbia, V6Z 1Y6, Canada

    Contact

  • Toronto General Hospital UHN

    RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

    Contact

  • University of Ottawa Heart Institute

    RECRUITING

    Ottawa, Ontario, K1Y 4W7, Canada

    Contact

Conditions

Explore the condition pages connected to this study.